Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02575963
Recruitment Status : Recruiting
First Posted : October 15, 2015
Last Update Posted : May 15, 2018
Information provided by (Responsible Party):
Actinium Pharmaceuticals